Clinical Trial Results:
A Long-term Follow-up of Study 64041575RSV2004 to Evaluate the Impact of Lumicitabine (JNJ-64041575) on the Incidence of Asthma and/or Wheezing in Infants and Children with a History of Respiratory Syncytial Virus Infection
Summary
|
|
EudraCT number |
2016-002095-26 |
Trial protocol |
GB FR ES DE BE PT FI SK IE IT |
Global end of trial date |
13 Apr 2020
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
25 Oct 2020
|
First version publication date |
25 Oct 2020
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
64041575RSV2002
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03332459 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Janssen- Cilag International NV
|
||
Sponsor organisation address |
Turnhoutseweg 30, Beerse, Belgium, B-2340
|
||
Public contact |
Clinical Registry Group, Janssen- Cilag International NV, ClinicalTrialsEU@its.jnj.com
|
||
Scientific contact |
Clinical Registry Group, Janssen- Cilag International NV, ClinicalTrialsEU@its.jnj.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
13 Apr 2020
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
13 Apr 2020
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
13 Apr 2020
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
The purpose of the study was to evaluate the incidence of the clinical diagnosis of asthma and the frequency of wheezing in infants and children who were treated with lumicitabine or placebo in Study 64041575RSV2004 during the follow-up period and within 2 years after the respiratory syncytial virus (RSV) infection.
|
||
Protection of trial subjects |
The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. Safety evaluations were based on the monitoring of adverse events (AEs) and serious adverse events (SAEs) throughout the study.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
09 Jan 2018
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Japan: 7
|
||
Worldwide total number of subjects |
7
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
6
|
||
Children (2-11 years) |
1
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||
Recruitment
|
|||||||||||||
Recruitment details |
Only subjects previously enrolled in study 64041575RSV2004 (EudraCT ID: 2017-001862-56) were eligible to enroll in this study. Only 7 subjects were enrolled in study 64041575RSV2004 before the study 64041575RSV2004 was prematurely terminated. | ||||||||||||
Pre-assignment
|
|||||||||||||
Screening details |
Total of 7 subjects were enrolled in this study from study 64041575RSV2004 and completed this study. | ||||||||||||
Period 1
|
|||||||||||||
Period 1 title |
Overall Study (overall period)
|
||||||||||||
Is this the baseline period? |
Yes | ||||||||||||
Allocation method |
Non-randomised - controlled
|
||||||||||||
Blinding used |
Double blind | ||||||||||||
Roles blinded |
Subject, Investigator, Carer | ||||||||||||
Arms
|
|||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||
Arm title
|
Placebo | ||||||||||||
Arm description |
Subjects who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received placebo for the treatment of Respiratory Syncytial Virus (RSV) infection, and who agreed to participate in this follow-up study were assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of placebo, frequency and type of respiratory infections and medical resource usage. | ||||||||||||
Arm type |
Placebo | ||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Powder for oral suspension
|
||||||||||||
Routes of administration |
Oral use
|
||||||||||||
Dosage and administration details |
Subjects who received placebo in a feeding Phase 2 study (64041575RSV2004) were observed. No study drug was administered in this study.
|
||||||||||||
Arm title
|
Lumicitabine 40/20 mg/kg regimen | ||||||||||||
Arm description |
Subjects who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received lumicitabine 40/20 milligrams per kilograms (mg/kg) for the treatment of RSV infection, and who agreed to participate in this follow-up study were assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of lumicitabine, frequency and type of respiratory infections and medical resource usage. | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
Lumicitabine
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Powder for oral suspension
|
||||||||||||
Routes of administration |
Oral use
|
||||||||||||
Dosage and administration details |
Subjects who received lumicitabine 40/20 mg/kg regimen in a feeding Phase 2 study (64041575RSV2004) were observed. No study drug was administered in this study.
|
||||||||||||
Arm title
|
Lumicitabine 60/40 mg/kg regimen | ||||||||||||
Arm description |
Subjects who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received lumicitabine 60/40 mg/kg for the treatment of RSV infection, and who agreed to participate in this follow-up study were assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of lumicitabine, frequency and type of respiratory infections and medical resource usage. | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
Lumicitabine
|
||||||||||||
Investigational medicinal product code |
|||||||||||||
Other name |
|||||||||||||
Pharmaceutical forms |
Powder for oral suspension
|
||||||||||||
Routes of administration |
Oral use
|
||||||||||||
Dosage and administration details |
Subjects who received lumicitabine 60/40 mg/kg regimen in a feeding Phase 2 study (64041575RSV2004) were observed. No study drug was administered in this study.
|
||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received placebo for the treatment of Respiratory Syncytial Virus (RSV) infection, and who agreed to participate in this follow-up study were assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of placebo, frequency and type of respiratory infections and medical resource usage. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Lumicitabine 40/20 mg/kg regimen
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received lumicitabine 40/20 milligrams per kilograms (mg/kg) for the treatment of RSV infection, and who agreed to participate in this follow-up study were assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of lumicitabine, frequency and type of respiratory infections and medical resource usage. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Lumicitabine 60/40 mg/kg regimen
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received lumicitabine 60/40 mg/kg for the treatment of RSV infection, and who agreed to participate in this follow-up study were assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of lumicitabine, frequency and type of respiratory infections and medical resource usage. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Placebo
|
||
Reporting group description |
Subjects who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received placebo for the treatment of Respiratory Syncytial Virus (RSV) infection, and who agreed to participate in this follow-up study were assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of placebo, frequency and type of respiratory infections and medical resource usage. | ||
Reporting group title |
Lumicitabine 40/20 mg/kg regimen
|
||
Reporting group description |
Subjects who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received lumicitabine 40/20 milligrams per kilograms (mg/kg) for the treatment of RSV infection, and who agreed to participate in this follow-up study were assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of lumicitabine, frequency and type of respiratory infections and medical resource usage. | ||
Reporting group title |
Lumicitabine 60/40 mg/kg regimen
|
||
Reporting group description |
Subjects who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received lumicitabine 60/40 mg/kg for the treatment of RSV infection, and who agreed to participate in this follow-up study were assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of lumicitabine, frequency and type of respiratory infections and medical resource usage. |
|
|||||||||||||||||
End point title |
Percentage of Subjects With Asthma After Respiratory Syncytial Virus (RSV) Infection [1] | ||||||||||||||||
End point description |
Percentage of subjects with asthma as diagnosed by a physician was reported. All Enrolled analysis set included all subjects from 64041575RSV2004 study who were enrolled in this long term follow up (LTFU) study.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Up to 2 Years
|
||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics were done, no inferential statistical analyses were performed. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Percentage of Wheezing Days in Subjects Within the First 2 Years After RSV Infection [2] | ||||||||||||||||
End point description |
Percentage of days with wheezing in subjects within the first 2 Years after RSV infection based on information reported by the parent/caregiver was reported. All Enrolled analysis set included all subjects from 64041575RSV2004 study who were enrolled in this LTFU study. Here '99999' indicates that the standard deviation was not evaluable as no wheezing day was observed in the specified group.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Up to 2 Years
|
||||||||||||||||
Notes [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics were done, no inferential statistical analyses were performed. |
|||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Percentage of Wheezing Days in Subjects per Month After RSV Infection | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Percentage of wheezing days in subjects per month after RSV infection based on information reported by the parent/caregiver was reported. All Enrolled analysis set included all subjects from the 64041575RSV2004 study who were enrolled in this LTFU study. Here '99999' indicates that the standard deviation was not evaluable as no wheezing day was observed in the specified group.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to 2 Years
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Wheezing Episodes in Subjects per Month After the RSV Infection | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Number of wheezing episodes in subjects per month after the RSV infection based on information reported by the parent/caregiver was reported. All Enrolled analysis set included all subjects from 64041575RSV2004 study who were enrolled in this LTFU study. Here '99999' indicates that the standard deviation was not evaluable as no wheezing episodes were observed in the specified group.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to 2 years
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of Subjects With Reportable Adverse Events (AEs) | ||||||||||||
End point description |
Number of subjects with reportable AEs was reported. The following AEs were considered reportable (within the context of this study): Respiratory illness AEs, including subsequent RSV infections, adverse events considered at least possibly related to study treatment (lumicitabine or placebo, as received in Study 64041575RSV2004), and serious adverse events. All Enrolled analysis set included all subjects from 64041575RSV2004 study who were enrolled in this LTFU study.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 2 Years
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Number of Subjects With Serious Adverse Events (SAEs) | ||||||||||||
End point description |
SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize subject and/or may require medical or surgical intervention to prevent one of the outcomes listed above. All Enrolled analysis set included all subjects from 64041575RSV2004 study who were enrolled in this LTFU study.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Up to 2 years
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Number of Respiratory Infections per Subject | ||||||||||||||||
End point description |
The number of respiratory infections among subjects, based on information reported by the parent/caregiver was reported. All Enrolled analysis set included all subjects from 64041575RSV2004 study who were enrolled in this LTFU study. Here ‘99999’ indicates that the standard deviation was not estimable as only one subject was analyzed for the respective arm.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Up to 2 Years
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Number of Subjects with Medical Encounters | ||||||||||||||||||||||||
End point description |
Number of subjects with medical encounters (Hospital inpatient department visits, hospital outpatient department visits, medical practitioner office visits) was reported based on information reported by the parent/caregiver. All Enrolled analysis set included all subjects from 64041575RSV2004 study who were enrolled in this LTFU study.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
Up to 2 Years
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Up to 2 years
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Reportable AEs (Respiratory illness AEs, including subsequent RSV infections, AEs considered at least possibly related to study treatment [lumicitabine or placebo, as received in Study 64041575RSV2004], and serious adverse events) reported below. All Enrolled analysis set: all subjects from 64041575RSV2004 study enrolled in this LTFU study.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
22.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received placebo for the treatment of Respiratory Syncytial Virus (RSV) infection, and who agreed to participate in this follow-up study were assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of placebo, frequency and type of respiratory infections and medical resource usage. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Lumicitabine 40/20 mg/kg regimen
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received lumicitabine 40/20 milligrams per kilograms (mg/kg) for the treatment of RSV infection, and who agreed to participate in this follow-up study were assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of lumicitabine, frequency and type of respiratory infections and medical resource usage. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Lumicitabine 60/40 mg/kg regimen
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received lumicitabine 60/40 mg/kg for the treatment of RSV infection, and who agreed to participate in this follow-up study were assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of lumicitabine, frequency and type of respiratory infections and medical resource usage. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
Due to the limited number of subjects enrolled in this study (n=7), no meaningful conclusions can be made. |